Altogether, these mechanisms highlight the dynamic interplay between CD8+ T cells and the TME, pointing out both the potential and the challenges of mounting an effective anti-tumor response by harnessing CD8+ T cells in cancer immunotherapy [21]. This evidence concerns the gene CD8A and neoplasm.